HOME >> BIOLOGY >> NEWS
Soliris (eculizumab) data to be presented at American Society of Hematology

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that abstracts relating to Soliris (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris (eculizumab) PNH clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website: www.hematology.org/meetings/abstracts.cfm. Access to the on-line abstracts may require registration, for which there is no charge.

The following abstracts will be presented in oral sessions:

  • "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria"
    Dr. Peter Hillmen et al.
    Time: Sunday, December 10th at 5:00pm
    Room 315
  • "Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III TRIUMPH Study Results"
    Dr. Jrg Schubert et al.
    Time: Sunday, December 10th at 5:15pm
    Room 315

The following abstracts will be presented in poster sessions:

  • "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study"
    Poster # 99-I
    Dr. Neal S. Young et al.
    Time: Saturday, December 9th at 9:00am
    Hall E-1
  • "Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization"
    Poster #100-I
    Dr. Anita Hill et
    '"/>


Contact: Tony Russo
tony.russo@eurorscg.com
212-845-4251
Euro RSCG Life NRP
8-Dec-2006


Page: 1 2

Related biology news :

1. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
2. Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip
3. Latest plant health research to be presented in San Diego
4. Presidential Recognition Awards presented at the 2007 AIUM Annual Convention
5. Agronomy, crop, soils research presented in Indianapolis
6. UW-Madison work on stem cells, cardiac health to be presented at ACS
7. Weizmann Women & Science Award presented to Dr. Mary-Claire King
8. IOF-Novartis Young Scholars Awards presented to seven researchers from six countries
9. Coma misrepresented in movies
10. Latest plant disease research to be presented in Quebec City
11. AIUM Presidential Recognition Awards presented

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... ), a clinical-stage pharmaceutical company focused on the ... that Dr. Miriam Kidron , Oramed,s Chief ... Insulin for Diabetes Treatment: Bypassing the Roadblock," at ... Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts ...
(Date:3/22/2017)... BEACH, Florida , March 22, 2017 ... ... for various cancer conditions are being pressured as of late ... therapy for cancer pain management has a dramatic impact on ... up research and development activities for identifying new forms of ...
Breaking Biology Technology:
Cached News: